NCT04345614Phase 2Completed

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-06-28Actual

Enrollment · participants314Actual

Source updated2026-03-30Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pneumonia

Treatments or interventions studied

Auxora (Part 1)DrugAlso known as CM4620-Injectable Emulsion (IE)
Standard of Care (Part 1)DrugAlso known as Placebo-Injectable Emulsion
Auxora (Part 2)DrugAlso known as CM4620-Injectable Emulsion (IE)
Placebo (Part 2)DrugAlso known as Placebo-Injectable Emulsion

Primary outcomes · main study measures

measure: Number of Days From the Start of the First Infusion of Study Drug (SFISD) to Recovery; description: Defined as the number of days hospitalized but not requiring supplemental oxygen or ongoing medical care, or; discharged and requiring supplemental oxygen, or; discharged, not requiring supplemental oxygen.; timeFrame: From start of first infusion of study drug to day 60

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history